Information:
Fel:
ID
15956
Beskrivning
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX); ODM derived from: https://clinicaltrials.gov/show/NCT02304354
Länk
https://clinicaltrials.gov/show/NCT02304354
Nyckelord
Versioner (1)
- 2016-06-21 2016-06-21 -
Uppladdad den
21 juni 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Rheumatoid Arthritis NCT02304354
Eligibility Rheumatoid Arthritis NCT02304354
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT02304354
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Rheumatoid Arthritis
Item
ra according to the american college of rheumatology (acr) criteria
boolean
C0003873 (UMLS CUI [1])
Therapeutic procedure adalimumab
Item
treatment with adalimumab in accordance to the spc
boolean
C0087111 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1122087 (UMLS CUI [1,2])
Antirheumatic Drugs, Disease-Modifying
Item
disease modifying anti rheumatic drugs (dmards) prescribed since 3 months and stable 4 weeks before enrollment and during 16 weeks.
boolean
C0242708 (UMLS CUI [1])
Informed consent
Item
signed consent
boolean
C0021430 (UMLS CUI [1])
anti-tumor necrosis factor therapy failed | Absent
Item
no anti tnf-alpha failure
boolean
C0281481 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C0332197 (UMLS CUI [2])
C0231175 (UMLS CUI [1,2])
C0332197 (UMLS CUI [2])
Prior Therapy rituximab
Item
previous rituximab treatment
boolean
C1514463 (UMLS CUI [1,1])
C0393022 (UMLS CUI [1,2])
C0393022 (UMLS CUI [1,2])
Medical contraindication adalimumab | Medical contraindication Methotrexate | Medical contraindication Methylprednisolone
Item
contraindication to adalimumab, methotrexate or methylprednisolone
boolean
C1301624 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C0025815 (UMLS CUI [3,2])
C1122087 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C0025815 (UMLS CUI [3,2])
Therapy naive Methotrexate
Item
methotrexate-naive patient
boolean
C0919936 (UMLS CUI [1,1])
C0025677 (UMLS CUI [1,2])
C0025677 (UMLS CUI [1,2])
Hematological Disease Affecting Lymphocyte | Hematological Disease Affecting Lymphoma
Item
any hematologic disease affecting the lymphocytes (in particular lymphomas)
boolean
C0018939 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0024264 (UMLS CUI [1,3])
C0018939 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0024299 (UMLS CUI [2,3])
C0392760 (UMLS CUI [1,2])
C0024264 (UMLS CUI [1,3])
C0018939 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0024299 (UMLS CUI [2,3])
Disease osteoarticular Interferes with research results | rituximab | Rheumatoid Arthritis
Item
any osteo-articular disease which could interfere with the interpretation of the influence of the rituximab on ra
boolean
C0012634 (UMLS CUI [1,1])
C0729915 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0683954 (UMLS CUI [1,4])
C0393022 (UMLS CUI [2])
C0003873 (UMLS CUI [3])
C0729915 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0683954 (UMLS CUI [1,4])
C0393022 (UMLS CUI [2])
C0003873 (UMLS CUI [3])